Cipla Update by Epic Research

Cipla, a global pharmaceutical company, has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of Sofosbuvir mono, Ledipasvir mono, the fixed-dose combination of Ledipasvir/Sofosbuvir with each other and the combination of Sofosbuvir or Ledipasvir with other active substances, for the treatment of Hepatitis C



Real Time News & Trading Trends Keep Liking #EpicResearch




Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+



For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH

Posted in: Indian Market Tips